Increased Concentrations of Apo A-I and Apo A-II Fragments in the Serum of Patients with Hepatocellular Carcinoma by Magnetic Beads-assisted MALDI-TOF Mass Spectrometry
Overview
Authors
Affiliations
Objectives: Recent advances in sophisticated technologies in proteomics should provide promising ways to discover novel markers for hepatocellular carcinoma (HCC) in the early diagnosis.
Methods: Serum peptide and protein profiling was conducted by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). Profiling was carried out in a training set of 16 patients with HCC and a testing set of 15 patients with cirrhosis without HCC. All the patients were hepatitis C virus positive. Candidate peaks were processed to partial purification, followed by protein identification by amino acid sequence analysis. Immunoprecipitation was conducted to confirm the protein identity.
Results: Partial purification and protein identification revealed that one peak that was up-regulated in HCC sera both in the training and the testing sets was a fragment of apolipoprotein A-I (apo A-I). Immunoprecipitation confirmed this result.
Conclusions: MALDI-TOF MS analysis revealed that apo A-I is a potential novel serum marker of HCC. Combination of these pretreatments and the current magnet bead-assisted MALDI-TOF MS will further enhance the efficiency of biomarker discovery for HCC.
Takahata Y, Hara M, Nishino K, Kawakami T Mass Spectrom (Tokyo). 2023; 12(1):A0122.
PMID: 37260735 PMC: 10227195. DOI: 10.5702/massspectrometry.A0122.
Cellular, Molecular and Proteomic Characteristics of Early Hepatocellular Carcinoma.
Armakolas A, Dimopoulou V, Nezos A, Stamatakis G, Samiotaki M, Panayotou G Curr Issues Mol Biol. 2022; 44(10):4714-4734.
PMID: 36286037 PMC: 9600540. DOI: 10.3390/cimb44100322.
Construction of 2DE Patterns of Plasma Proteins: Aspect of Potential Tumor Markers.
Naryzhny S, Ronzhina N, Zorina E, Kabachenko F, Klopov N, Zgoda V Int J Mol Sci. 2022; 23(19).
PMID: 36232415 PMC: 9569744. DOI: 10.3390/ijms231911113.
Apolipoprotein: prospective biomarkers in digestive tract cancer.
Zhang Y, Zheng L Transl Cancer Res. 2022; 9(5):3712-3720.
PMID: 35117733 PMC: 8799137. DOI: 10.21037/tcr-19-2106.
Ni X, Yi Y, Fu Y, Cai X, Liu G, Huang J Onco Targets Ther. 2020; 13:12867-12880.
PMID: 33376344 PMC: 7756018. DOI: 10.2147/OTT.S279997.